New Oracle, Gilead Sciences & TOTAL Research Reports

Wednesday, September 14, 2016

Today's Research Daily features new research reports on 16 major stocks, including TOTAL (TOT), Oracle (NYSE:ORCL) and Gilead Sciences (NASDAQ:GILD). Please note that these 16 reports have been handpicked from the more than 80 research reports issued by our analyst team today. You can see the complete list of today's research reports here >>>

Shares of French oil major TOTAL have come down in recent days, as have other oil stocks, in response to weakness in the commodity on IEA’s dismal global oil demand forecasts. But this Zacks Rank # 2 (Buy) stock is still up nicely on the year, with the company making a concerted effort to increase its footprint in the U.S. The recent deal to acquire Chesapeake's stake in the prolific Barnett Shale basin is a step in that direction. The Zacks analyst likes the company’s efforts to that end and explains them in detail in the research report published today. (You can read the full research report on TOTAL here>>)

Oracle shares have been strong performers this year, up more than 10% year-to-date, on the back of favorable momentum in its cloud-based products, SaaS and PaaS that are expected to be key growth drivers in its quarterly report coming out after the close on Thursday (September 15th). The Zacks analyst likes the company’s Big Data and digitalization initiatives, which is expected to boost its database management system growth. However, Oracle’s business transition from licensing to cloud is a drag on the financials at present. It lost a JAVA APIs lawsuit against Alphabet’s Google (NASDAQ:GOOGL) and another Itanium software lawsuit against HPE, which also remains an overhang on the stock. (You can read the full research report on Oracle here>>)

Gilead Sciences shares have been laggards this year, losing nearly 22.9% year-to-date, as the HCV franchise continues to witness slowdown in the U.S. and Europe due to lower sales of Harvoni. Gilead lowered its 2016 product sales outlook, reflecting the current trends in the payer and patient flow dynamics for HCV among other factors. Despite these concerns, the Zacks analyst likes the company’s well performing HIV franchise, which is expected to get a further boost from its newly launched HIV treatments like Genvoya. The company also has a robust late-stage pipeline that bodes well for its long-term growth. (You can read the full research report on Gilead Sciences here>>)

Other noteworthy reports today include JPMorgan Chase (NYSE:JPM), which has been downgraded to Zacks Rank # 4 (Sell), and Equinix (NASDAQ:EQIX), which moves up to Zacks Rank # 2 (Buy).

You can find all of today's stock research reports here>>

Today's Long-Term Buys & Sells

Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here >>